Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alnylam Pharmaceuticals

251.15
-7.2000-2.79%
Post-market: 251.150.00000.00%17:28 EDT
Volume:656.36K
Turnover:166.30M
Market Cap:32.75B
PE:-119.69
High:260.00
Open:259.92
Low:250.35
Close:258.35
Loading ...
Aug 06, 2020

Major Issues Report

8-K - Current report
May 11, 2020

Major Issues Report

Current report, items 5.07 and 9.01
May 06, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 06, 2020

Major Issues Report

Current report, items 2.02 and 9.01
Apr 13, 2020

Major Issues Report

8-K - Current report
Apr 06, 2020

Major Issues Report

Current report, items 1.01, 7.01, 8.01, and 9.01
Feb 27, 2020

Major Issues Report

8-K - Current report
Feb 13, 2020

Employee Stock Ownership

Securities to be offered to employees in employee benefit plans
Feb 13, 2020

Annual Report

Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 12, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 12, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 07, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 06, 2020

Major Issues Report

Current report, items 2.02 and 9.01
Feb 05, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 03, 2020

Beneficial Ownership Change

Statement of acquisition of beneficial ownership by individuals
Jan 28, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Jan 13, 2020

Major Issues Report

Current report, items 2.02 and 9.01
Nov 20, 2019

Major Issues Report

Current report, items 8.01 and 9.01
Oct 31, 2019

Quarterly Report

Quarterly report [Sections 13 or 15(d)]
Oct 31, 2019

Major Issues Report

Current report, items 2.02 and 9.01